Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity

Bibliography

• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84
   PubMed Web of Science ®Google Scholar
• Nagy VM, Ordeanu C, Coza O, et al. Randomized phase 3 trial comparing 2 cisplatin dose schedules in 326 patients with locally advanced squamous cell cervical carcinoma: long-term follow-up. Int J Gynecol Cancer 2012;22:1538-44
   Google Scholar
• Tsan DL, Lin CY, Kang CJ, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 2012;7:215
   PubMed Web of Science ®Google Scholar
• Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969;222:385-6
   PubMed Web of Science ®Google Scholar
• Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20
   PubMed Web of Science ®Google Scholar
• Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001;59:657-63
   PubMed Web of Science ®Google Scholar
• Sancho-Martínez SM, Prieto-García L, Prieto M, et al. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 2012;136:35-55
   PubMed Web of Science ®Google Scholar
• Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 2008;15:2656-63
   PubMed Web of Science ®Google Scholar
• Burstyn JN, Heiger-Bernays WJ, Cohen SM, Lippard SJ. Formation of cis-diamminedichloroplatinum (II) 1, 2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acid Res 2000;28:4237-43
   PubMed Web of Science ®Google Scholar
• Fuertes MA, Castilla J, Alonso C, Pérez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003;10:257-66
   PubMed Web of Science ®Google Scholar
• Sorenson CM, Eastman A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 1988;48:6703-7
   PubMedGoogle Scholar
• Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-55
   PubMed Web of Science ®Google Scholar
• Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8
   PubMed Web of Science ®Google Scholar
• Sancho-Martínez SM, Piedrafita FJ, Cannata-Andía JB, et al. Necrotic concentrations of cisplatin activate the apoptotic machinery but inhibit effector caspases and interfere with the execution of apoptosis. Toxicol Sci 2011;122:73-85
   PubMed Web of Science ®Google Scholar
• Martin DS, Bertino JR, Koutcher JA. ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Cancer Res 2000;60:6776-83
   PubMed Web of Science ®Google Scholar
• Jensen M, Bjerring M, Nielsen NC, Nerdal W. Cisplatin interaction with phosphatidylserine bilayer studied by solid-state NMR spectroscopy. J Biol Inorg Chem 2010;15:213-23
   Google Scholar
• Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004;64:3593-8
   PubMed Web of Science ®Google Scholar
• López-Lázaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 2008;8:305-12
   PubMed Web of Science ®Google Scholar
• Annibaldi A, Widmann C. Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care 2010;13:466-70
   PubMed Web of Science ®Google Scholar
• Porporato PE, Dhup S, Dadhich RK, et al. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011;2:49
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956;123:309-14
   PubMed Web of Science ®Google Scholar
• Tomiyama A, Serizawa S, Tachibana K, et al. Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 2006;98:1462-73
   PubMedGoogle Scholar
• Wong JY, Huggins GS, Debidda M, et al. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 2008;109:394-402
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99:989-94
   PubMed Web of Science ®Google Scholar
• Feuerecker B, Pirsig S, Seidl C, et al. Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther 2012;13:1425-35
   PubMed Web of Science ®Google Scholar
• Liang XJ, Finkel T, Shen DW, et al. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 2008;6:1499-506
   PubMed Web of Science ®Google Scholar
• Goldstein RS, Mayor GH, Rosenbaum RW, et al. Glucose intolerance following cis-platinum treatment in rats. Toxicology 1982;24(3-4):273-80
   Google Scholar
• Safirstein RL. Acute renal failure: from renal physiology to the renal transcriptome. Kidney Int 2004;66:S62-6.
   Google Scholar
• Egawa-Takata T, Endo H, Fujita M, et al. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. Cancer Sci 2010;101:2171-8
   PubMed Web of Science ®Google Scholar
• Shulga N, Wilson-Smith R, Pastorino JG. Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 2009;8:3355-64
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64:3892-9
   PubMed Web of Science ®Google Scholar
• Zhang LL, Zhang J, Shen L, et al. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo. Mol Med Rep 2013;7:1387-90
   Google Scholar
• Demaria M, Giorgi C, Lebiedzinska M, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging 2010;2:823-42
   PubMedGoogle Scholar
• Gough DJ, Corlett A, Schlessinger K, et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009;324:1713-16
   PubMed Web of Science ®Google Scholar
• Han Z, Feng J, Hong Z, et al. Silencing STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Byophys Res Commun 2013; published online 7 May 2013; doi: 10.1016/j.bbrc.2013.04.087
   Google Scholar
• Olszewski U, Poulsen TT, Ulsperger E, et al. In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin Pharmacol 2010;2:177-83
   Google Scholar
• Xie J, Wang BS, Yu DH, et al. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. Int J Oncol 2011;38:409-17
   PubMed Web of Science ®Google Scholar
• Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3-Bromopyruvate as inhibitor of tumor cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008;2:94-101
   PubMed Web of Science ®Google Scholar
• Simons AL, Ahmad IM, Mattson DM, et al. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007;67:3364-70
   PubMed Web of Science ®Google Scholar
• Masuda H, Tanaka T, Tateishi M, et al. Detection and cytotoxicity of cisplatin-induced superoxide anion in monolayer cultures of a human ovarian cancer cell line. Cancer Chemother Pharmacol 2001;47:155-60
   PubMed Web of Science ®Google Scholar
• Srivastava AN, Gupta A, Srivastava S, et al. Cisplatin combination chemotherapy induces oxidative stress in advance non-small cell lung cancer patients. Asian Pac J Cancer Prev 2010;11:465-71
   PubMed Web of Science ®Google Scholar
• Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev 2012;70:257-65
   PubMed Web of Science ®Google Scholar
• Spitz DR, Phillips JW, Adams DT, et al. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J Cell Physiol 1993;156:72-9
   PubMed Web of Science ®Google Scholar
• Srivastava AN, Gupta A, Srivastava S, et al. Cisplatin combination chemotherapy induces oxidative stress in advance non-small cell lung cancer patients. Asian Pac J Cancer Prev 2010;11:465-71
   PubMed Web of Science ®Google Scholar
• Kasherman Y, Sturup S, Gibson D. Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts. J Med Chem 2009;52:4319-28
   PubMed Web of Science ®Google Scholar
• Kadikoylu G, Bolaman Z, Demir S, et al. The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 2004;23:29-34
   PubMed Web of Science ®Google Scholar
• Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 2000;41:405-11
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Shoji T, Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992;43:1872-5
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79
   PubMed Web of Science ®Google Scholar
• Martins NM, Santos NA, Curti C, et al. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 2008;28:337-44
   PubMed Web of Science ®Google Scholar
• Santos NA, Catão CS, Martins NM, et al. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007;81:495-504
   PubMed Web of Science ®Google Scholar
• Traber MG, Sokol RJ, Ringel SP, et al. Lack of α-tocopherol in peripheral nerves of vitamin E deficient patients with peripheral neuropathy. N Engl J Med 1987;317:262-5
   PubMed Web of Science ®Google Scholar
• Chirino YI, Pedraza-Chaverry J. Role of oxidative stress and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223-42
   PubMed Web of Science ®Google Scholar
• Wainford RD, Weaver RJ, Stewart KN, et al. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology 2008;249:184-93
   PubMedGoogle Scholar
• Stewart DJ, Dulberg C, Molepo JM, et al. Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Cancer Chemother Pharmacol 1994;34:14-22
   Google Scholar
• Sánchez-González PD, López-Hernández FJ, López-Novoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 2011;41:803-21
   PubMed Web of Science ®Google Scholar
• Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115-24
   PubMed Web of Science ®Google Scholar
• Jung M, Hotter G, Viñas JL, Sola A. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. Toxicol Appl Pharmacol 2009;234:236-46
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007
   PubMed Web of Science ®Google Scholar
• Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996;270:F700-8
   PubMed Web of Science ®Google Scholar
• Ueda N, Shah SV. Tubular cell damage in acute renal failure-apoptosis, necrosis, or both. Nephrol Dial Transplant 2000;15:318-23
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003;285:F610-18
   PubMed Web of Science ®Google Scholar
• Santos NA, Bezerra CS, Martins NM, et al. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008;61:145-55
   PubMed Web of Science ®Google Scholar
• Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008;327:300-7
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-4
   PubMed Web of Science ®Google Scholar
• Brillet G, Deray G, Jacquiaud C, et al. Long-term renal effect of cisplatin in man. Am J Nephrol 1994;14:81-4
   Web of Science ®Google Scholar
• Greystoke AP, Jodrell DI, Cheung M, et al. How many cisplatin administration protocols does your department use? Eur J Cancer Care (Engl) 2010;19:80-90
   Google Scholar
• Forrester SD, Fallin EA, Saunders GK, Kenny JE. Prevention of cisplatin-induced nephrotoxicosis in dogs, using hypertonic saline solution as the vehicle of administration. Am J Vet Res 1993;54:2175-8
   Google Scholar
• Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-81
   PubMed Web of Science ®Google Scholar
• Morgan KP, Buie LW, Savage SW. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother 2012;46:276-81
   Google Scholar
• Santoso JT, Lucci JA III, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003;52:13-18
   PubMed Web of Science ®Google Scholar
• Muraki K, Koyama R, Honma Y, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis 2012;4:562-8
   Google Scholar
• Jacobs C, Kaubisch S, Halsey J, et al. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 1991;67:1518-24
   PubMed Web of Science ®Google Scholar
• dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012;86:1233-50
   PubMed Web of Science ®Google Scholar
• Katsuda H, Yamashita M, Katsura H, et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 2010;33:1867-71
   PubMed Web of Science ®Google Scholar
• Uozumi J, Koikawa Y, Yasumasu T, et al. The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors. Int J Urol 1996;3:343-7
   Google Scholar
• Offerman JJ, Mulder NH, Sleijfer DT, et al. Influence of captopril on cis-diamminedichloroplatinum-induced renal toxicity. Am J Nephrol 1985;5:433-6
   Google Scholar
• Offerman JJ, Meijer S, Sleijfer DT, et al. The influence of verapamil on renal function in patients treated with cisplatin. Clin Nephrol 1985;24:249-55
   PubMedGoogle Scholar
• Uozumi J, Ueda T, Yasumasu T, et al. Calcium blockers enhance cisplatin-induced nephrotoxicity in rats. Int Urol Nephrol 1992;24:549-53
   PubMedGoogle Scholar
• Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995;95:1650-9
   PubMed Web of Science ®Google Scholar
• Neumcke I, Schneider B, Fandrey J, Pagel H. Effects of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology 1999;140:641-5
   Google Scholar
• Tjulandin SA, Bias P, Elsässer R, et al. Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial. Arch Drug Inf 2010;3:45-53
   PubMedGoogle Scholar
• Kong D, Zhuo L, Gao C, et al. Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-induced apoptosis. J Nephrol 2013;26:219-27
   PubMed Web of Science ®Google Scholar
• Rjiba-Touati K, Boussema IA, Belarbia A, et al. Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol 2011;30:510-17
   PubMed Web of Science ®Google Scholar
• Kedar A, Cohen ME, Freeman AI. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report. Cancer Treat Rep 1978;62:819-21
   PubMedGoogle Scholar
• Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010;74:762-6
   PubMed Web of Science ®Google Scholar
• Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;66:1117-23
   PubMed Web of Science ®Google Scholar
• Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007;130:1076-88
   PubMedGoogle Scholar
• Authier N, Gillet JP, Fialip J, et al. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003;182:12-20
   PubMed Web of Science ®Google Scholar
• Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54:1269-75
   PubMed Web of Science ®Google Scholar
• Isonaka R, Hiruma H, Kawakami T. Inhibition of axonal transport caused by tert-butyl hydroperoxide in cultured mouse dorsal root ganglion neurons. J Mol Neurosci 2011;45:194-201
   Google Scholar
• McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005;18:305-13
   PubMed Web of Science ®Google Scholar
• Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012;291:1-9
   PubMed Web of Science ®Google Scholar
• Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol 2006;2:620-8
   PubMedGoogle Scholar
• Carozzi VA, Marmiroli P, Cavaletti G. The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug Targets 2010;10:670-82
   PubMed Web of Science ®Google Scholar
• Roila F, Hesketh PJ, Herrstedt J; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8
   PubMed Web of Science ®Google Scholar
• Miller AD, Nonaka S, Jakus J. Brain areas essential or non-essential for emesis. Brain Res 1994;647:255-64
   Google Scholar
• Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43
   PubMedGoogle Scholar
• Fozard JR, Mobarok ALI AT. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978;49:109-12
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 1981;305:905-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Hamaue N, Endo T, et al. 5-hydroxytryptamine (5-HT) concentrations in the hippocampus, the hypothalamus and the medulla oblongata related to cisplatin-induced pica of rats. Res Commun Mol Pathol Pharmacol 2003;113-114:97-113
   Google Scholar
• Endo T, Minami M, Hirafuji M, et al. Neurochemistry and neuropharmacology of emesis - the role of serotonin. Toxicology 2000;153(1-3):189-201
   PubMed Web of Science ®Google Scholar
• Chauhan P, Sodhi A, Shrivastava A. Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells. Immunobiology 2009;214:197-209
   Google Scholar
• Mantovani G, Macciò A, Esu S, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997;33:602-7
   PubMedGoogle Scholar
• Mantovani G, Macciò A, Esu S, Lai P. Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Eur J Cancer 1996;32A:1983-5
   Google Scholar
• Minami M, Endo T, Hirafuji M, et al. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther 2003;99:149-65
   PubMed Web of Science ®Google Scholar
• Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997;33:1364-70
   PubMed Web of Science ®Google Scholar
• Blower PR. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 2003;11:93-100
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Kwong DL, et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol 2000;23:185-91
   PubMed Web of Science ®Google Scholar
• Wu G, Fang YZ, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr 2004;134:489-92
   PubMed Web of Science ®Google Scholar
• Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 2007;113:234-58
   PubMedGoogle Scholar
• Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011(2):CD005228
   Google Scholar
• Xu YY, Jiang N, Liu TS, et al. Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times. Mol Med Rep 2012;6:1075-80
   PubMed Web of Science ®Google Scholar
• Chen HH, Kuo MT. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010;2010: pii: 430939
   PubMedGoogle Scholar
• Sinha-Hikim I, Shen R, Paul Lee WN, et al. Effects of a novel cystine-based glutathione precursor on oxidative stress in vascular smooth muscle cells. Am J Physiol Cell Physiol 2010;299:C638-42
   Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 2003;37:213-23
   PubMed Web of Science ®Google Scholar
• Roy S, Packer L. Redox regulation of cell functions by alpha-lipoate: biochemical and molecular aspects. Biofactors 1998;8:17-21
   PubMed Web of Science ®Google Scholar
• Flohé L, Brigelius-Flohé R, Saliou C, et al. Redox regulation of NF-kappa B activation. Free Radic Biol Med 1997;22:1115-26
   PubMed Web of Science ®Google Scholar
• El-Beshbishy HA, Bahashwan SA, Aly HA, Fakher HA. Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur J Pharmacol 2011;668:278-84
   PubMed Web of Science ®Google Scholar
• Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008;214:276-84
   PubMed Web of Science ®Google Scholar
• Tuncer S, Dalkilic N, Akif Dunbar M, Keles B. Comparative effects of α lipoic acid and melatonin on cisplatin-induced neurotoxicity. Int J Neurosci 2010;120:655-63
   PubMed Web of Science ®Google Scholar
• Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007;12:738-47
   PubMed Web of Science ®Google Scholar
• Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999;26(2 Suppl 7):72-81
   PubMed Web of Science ®Google Scholar
• Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61(11):2192-5
   PubMed Web of Science ®Google Scholar
• Markman M. Amifostine in reducing cisplatin toxicity. Semin Oncol 1998;25:522-4
   Google Scholar
• Somani SM, Ravi R, Rybak LP. Diethyldithiocarbamate protection against cisplatin nephrotoxicity: antioxidant system. Drug Chem Toxicol 1995;18:151-70
   PubMed Web of Science ®Google Scholar
• Bodenner DL, Dedon PC, Keng PC, et al. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res 1986;46:2751-5
   PubMed Web of Science ®Google Scholar
• Sooriyaarachchi M, Narendran A, Gailer J. The effect of sodium thiosulfate on the metabolism of cisplatin in human plasma in vitro. Metallomics 2012;4:960-7
   Google Scholar
• Oprea A, Bazzazi H, Kangarloo B, Wolff JE. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxaliplatin and carboplatin. Anticancer Res 2001;21:1225-9
   Google Scholar
• Gispen WH, Hamers FP, Vecht CJ, et al. ACTH/MSH like peptides in the treatment of cisplatin neuropathy. Steroid Biochem Mol Biol 1992;43:179-83
   Google Scholar
• van der Hoop RG, Hamers FP, Neijt JP, et al. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 1994;126:109-15
   Google Scholar
• van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;322:89-94
   PubMed Web of Science ®Google Scholar
• Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev 2010(1):CD006272
   Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
   PubMed Web of Science ®Google Scholar
• Leander S, Håkanson R, Rosell S, et al. A specific substance P antagonist blocks smooth muscle contractions induced by non-cholinergic, non-adrenergic nerve stimulation. Nature 1981;294:467-9
   PubMed Web of Science ®Google Scholar
• Snider RM, Constantine JW, Lowe JA III, et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991;251:435-7
   PubMed Web of Science ®Google Scholar
• Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250:R5-6
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
   PubMed Web of Science ®Google Scholar
• Tarladacalisir YT, Kanter M, Uygun M. Protective effects of vitamin C on cisplatin-induced renal damage: a light and electron microscopic study. Ren Fail 2008;30:1-8
   PubMed Web of Science ®Google Scholar
• Ajith TA, Abhishek G, Roshny D, Sudheesh NP. Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol 2009;61:565-71
   PubMed Web of Science ®Google Scholar
• Dillioglugil MO, Maral Kir H, Gulkac MD, et al. Protective effects of increasing vitamin E and A doses on cisplatin-induced oxidative damage to kidney tissue in rats. Urol Int 2005;75:340-4
   PubMed Web of Science ®Google Scholar
• Do Amaral CL, Francescato HD, Coimbra TM, et al. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 2008;82:363-70
   PubMed Web of Science ®Google Scholar
• Francescato HD, Coimbra TM, Costa RS, Bianchi Mde L. Protective effect of quercetin on the evolution of cisplatin-induced acute tubular necrosis. Kidney Blood Press Res 2004;27:148-58
   PubMed Web of Science ®Google Scholar
• Ozen S, Akyol O, Iraz M, et al. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol 2004;24:27-35
   PubMed Web of Science ®Google Scholar
• Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 2005;76:2125-35
   PubMed Web of Science ®Google Scholar
• Atessahin A, Yilmaz S, Karahan I, et al. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 2005;212:116-23
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, et al. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant 2011;26:3484-95
   PubMed Web of Science ®Google Scholar
• Al Moundhri MS, Al-Salam S, Al Mahrouqee A, et al. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. J Med Toxicol 2013;9:25-33
   PubMedGoogle Scholar
• Mendonça LM, da Silva Machado C, Correia Teixeira CC, et al. Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. Neurotoxicology 2013;34:205-11
   PubMed Web of Science ®Google Scholar
• Satya-Murti S, Howard L, Krohel G, Wolf B. The spectrum of neurological disorder from vitamin E deficiency. Neurology 1986;36:917-21
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 2006;14:1134-40
   PubMed Web of Science ®Google Scholar
• Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010;74:762-6
   PubMed Web of Science ®Google Scholar
• Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927-31
   PubMed Web of Science ®Google Scholar
• Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32
   PubMed Web of Science ®Google Scholar
• Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 1997;11:388-95
   PubMed Web of Science ®Google Scholar
• Kwee TC, Basu S, Saboury B, et al. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging 2011;38:1158-70
   PubMed Web of Science ®Google Scholar
• Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005;97:436-41
   PubMed Web of Science ®Google Scholar
• Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109:477-86
   PubMed Web of Science ®Google Scholar
• Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev 2013;39:270-4
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-21
   PubMed Web of Science ®Google Scholar
• Rose PG, Ali S, Watkins E, Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2804-10
   PubMed Web of Science ®Google Scholar
• Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-49
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Köhrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996;7:1015-21
   PubMed Web of Science ®Google Scholar